Want to see JP:4539 full AI Analyst Report?

Nippon Chemiphar Co., Ltd. (4539) Price & Analysis

1 Followers

4539 Stock Chart & Stats

¥1585.00

-¥7.00(-0.46%)

At close: Jan 08 4:00 PM EST

¥1585.00

-¥7.00(-0.46%)

Day’s Range― - ―

52-Week Range¥1,480.00 - ¥1,857.00

Previous CloseN/A

Volume500.00

Average Volume (3M)2.30K

Market Cap

¥5.86B

Enterprise Value¥16.93B

Total Cash (Recent Filing)¥9.69B

Total Debt (Recent Filing)¥19.02B

Price to Earnings (P/E)29.6

Beta0.21

Next Earnings

Jul 31, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield3.21%

Share Statistics

EPS (TTM)109.50

Shares Outstanding4,261,420

10 Day Avg. Volume1,680

30 Day Avg. Volume2,300

Financial Highlights & Ratios

PEG Ratio-0.99

Price to Book (P/B)0.33

Price to Sales (P/S)0.19

P/FCF Ratio-27.85

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth RecoveryA sharp revenue rebound into 2026 indicates renewed product demand or successful launches and materially improves scale. Sustained top-line momentum can fund R&D, support fixed-cost absorption and enable margin improvement over multiple quarters if the company maintains execution.

Balance-sheet StabilityModerate leverage and stable asset/equity levels provide financial flexibility. With debt declining in 2026, the company is better positioned to finance operations, absorb shocks, pursue selective M&A or R&D, and maintain supplier and customer confidence over the medium term.

Durable Business Model (generics & Prescriptions)A focus on prescription drugs and generics creates a stable, volume-driven revenue base tied to Japan's healthcare system. Generics provide recurring orders and margin stability via manufacturing scale, while in-house/contract production supports supply reliability and long-term customer relationships.

Bears Say

Weak Cash GenerationPersistent negative free cash flow limits the firm's ability to self-fund R&D, capital expenditures and dividends without tapping debt or equity. Volatile operating cash flows increase refinancing risk and reduce resilience to reimbursement or demand shocks over the medium term.

Inconsistent Profitability And Thin MarginsVolatile profitability and narrow margins make earnings unpredictable and hinder reinvestment. Susceptibility to single-year swings implies limited pricing power or concentration risks, which can impair returns and strategic planning if structural cost or reimbursement pressures persist.

Low And Uneven Returns On CapitalLow/negative ROE indicates the company struggles to convert capital into sustainable profits, limiting shareholder value creation. This constrains the ability to attract capital, pursue growth investments, or absorb competitive pressure without diluting returns over the medium term.

4539 FAQ

What was Nippon Chemiphar Co., Ltd.’s price range in the past 12 months?

Nippon Chemiphar Co., Ltd. lowest stock price was ¥1480.00 and its highest was ¥1857.00 in the past 12 months.

What is Nippon Chemiphar Co., Ltd.’s market cap?

Nippon Chemiphar Co., Ltd.’s market cap is ¥5.86B.

When is Nippon Chemiphar Co., Ltd.’s upcoming earnings report date?

Nippon Chemiphar Co., Ltd.’s upcoming earnings report date is Jul 31, 2026 which is in 14 days.

How were Nippon Chemiphar Co., Ltd.’s earnings last quarter?

Nippon Chemiphar Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥24.67 earnings per share for the quarter, missing the consensus estimate of N/A by -¥24.67.

Is Nippon Chemiphar Co., Ltd. overvalued?

According to Wall Street analysts Nippon Chemiphar Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nippon Chemiphar Co., Ltd. pay dividends?

Nippon Chemiphar Co., Ltd. pays a Annually dividend of ¥50 which represents an annual dividend yield of 3.21%. See more information on Nippon Chemiphar Co., Ltd. dividends here

What is Nippon Chemiphar Co., Ltd.’s EPS estimate?

Nippon Chemiphar Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nippon Chemiphar Co., Ltd. have?

Nippon Chemiphar Co., Ltd. has 4,261,420 shares outstanding.

What happened to Nippon Chemiphar Co., Ltd.’s price movement after its last earnings report?

Nippon Chemiphar Co., Ltd. reported an EPS of -¥24.67 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.057%.

Which hedge fund is a major shareholder of Nippon Chemiphar Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4539

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nippon Chemiphar Co., Ltd.

Nippon Chemiphar Co., Ltd., alongside its subsidiaries, is a global pharmaceutical entity engaged in the research, production, marketing, and sale of ethical drugs and diagnostic agents. Its diagnostic product lineup features the IgE NC kit, which measures overall IgE levels and identifies 57 specific allergens, as well as the DP3000 device for accurate allergen-specific IgE testing. The company's development pipeline includes NC-2400, a PPAR-delta agonist; NC-2500, a novel xanthine oxidoreductase inhibitor targeting hyperuricemia and gout; and NC-2600, a P2X4 receptor antagonist for neuropathic pain. Additionally, it is advancing NC-2700, a new urate transporter 1 inhibitor designed to enhance urinary urate excretion, and NC-2800, a delta opioid receptor agonist for treating depression and anxiety. Its commercialized pharmaceuticals comprise Uralyt-U (an alkalization therapeutic), Soleton (an analgesic and anti-inflammatory medication), and Calvan (a drug for hypertension). Beyond pharmaceuticals, Nippon Chemiphar offers a variety of quasi-drugs, nutritional supplements, health foods, cosmetics, and different types of creams. Its generic medications reach hospitals and pharmacies via wholesale distributors. Founded in Tokyo, Japan, in 1950, the company was initially known as Hitachi Chemical Co., Ltd., changing its name to Nippon Chemiphar Co., Ltd. in 1970.